ARCTURUS THERAPEUTICS HOLDINGS INC. Foreign Currency Transaction Gain (Loss), before Tax
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Foreign Currency Transaction Gain (Loss), before Tax of $382.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $701.00K, a 309.94% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$170.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-06-30 was -$127.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-03-31 was -$21.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was $382.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$471.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$229.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$598.00K, a 202.40% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $531.00K derived: sum of 2 quarters · filed 2026-03-03 | $404.00K derived: sum of 3 quarters · filed 2026-03-03 | $382.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | -$170.00K 10-Q · filed 2025-11-12 | -$297.00K derived: sum of 2 quarters · filed 2025-11-12 | -$319.00K 10-Q · filed 2025-11-12 | -$147.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | -$127.00K 10-Q · filed 2025-08-11 | -$149.00K 10-Q · filed 2025-08-11 | $23.00K derived: sum of 3 quarters · filed 2026-03-03 | -$178.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | -$21.00K 10-Q · filed 2025-05-12 | $150.00K derived: sum of 2 quarters · filed 2026-03-03 | -$51.00K derived: sum of 3 quarters · filed 2026-03-03 | -$439.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$30.00K derived: sum of 2 quarters · filed 2026-03-03 | -$418.00K derived: sum of 3 quarters · filed 2026-03-03 | -$471.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | -$201.00K 10-Q · filed 2025-11-12 | -$589.00K derived: sum of 2 quarters · filed 2025-11-12 | -$642.00K 10-Q · filed 2025-11-12 | -$696.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$388.00K 10-Q · filed 2025-08-11 | -$441.00K 10-Q · filed 2025-08-11 | -$495.00K derived: sum of 3 quarters · filed 2026-03-03 | -$491.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$53.00K 10-Q · filed 2025-05-12 | -$107.00K derived: sum of 2 quarters · filed 2026-03-03 | -$103.00K derived: sum of 3 quarters · filed 2026-03-03 | $46.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$50.00K derived: sum of 2 quarters · filed 2026-03-03 | $99.00K derived: sum of 3 quarters · filed 2026-03-03 | -$229.00K 10-K · filed 2026-03-03 |
| 2023-09-30 | $4.00K 10-Q · filed 2024-11-07 | $153.00K derived: sum of 2 quarters · filed 2024-11-07 | -$175.00K 10-Q · filed 2024-11-07 | -$4.01M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $149.00K 10-Q · filed 2024-08-05 | -$179.00K 10-Q · filed 2024-08-05 | -$4.01M derived: sum of 3 quarters · filed 2025-03-06 | -$2.15M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$328.00K 10-Q · filed 2024-05-08 | -$4.16M derived: sum of 2 quarters · filed 2025-03-06 | -$2.30M derived: sum of 3 quarters · filed 2025-03-06 | -$1.08M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.97M derived: sum of 2 quarters · filed 2025-03-06 | -$756.00K derived: sum of 3 quarters · filed 2025-03-06 | -$598.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $1.86M 10-Q · filed 2023-11-14 | $3.08M derived: sum of 2 quarters · filed 2023-11-14 | $3.24M 10-Q · filed 2023-11-14 | $2.90M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-07 | $1.38M 10-Q · filed 2023-08-07 | $1.04M derived: sum of 3 quarters · filed 2024-03-14 | $1.54M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $158.00K 10-Q · filed 2023-05-09 | -$181.00K derived: sum of 2 quarters · filed 2024-03-14 | $325.00K derived: sum of 3 quarters · filed 2024-03-14 | $312.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $167.00K derived: sum of 2 quarters · filed 2024-03-14 | $154.00K derived: sum of 3 quarters · filed 2024-03-14 | $584.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $506.00K 10-Q · filed 2022-11-09 | $493.00K derived: sum of 2 quarters · filed 2022-11-09 | $923.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$13.00K 10-Q · filed 2022-08-09 | $417.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $430.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |